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Abstract
Aromatase, the key enzyme in estrogen biosynthesis, converts androstenedione to estrone and testosterone to
estradiol. The enzyme is expressed in various tissues such as ovary, placenta, bone, brain, skin, and adipose tissue.
Aromatase enzyme is encoded by a single gene CYP 19A1 and its expression is controlled by tissue-specific promoters.
Aromatase mRNA is primarily transcribed from promoter I.4 in normal breast tissue and physiological levels of
aromatase are found in breast adipose stromal fibroblasts. Under the conditions of breast cancer, as a result of the
activation of a distinct set of aromatase promoters (I.3, II, and I.7) aromatase expression is enhanced leading to local
overproduction of estrogen that promotes breast cancer. Aromatase is considered as a potential target for endocrine
treatment of breast cancer but due to nonspecific reduction of aromatase activity in other tissues, aromatase inhibitors
(AIs) are associated with undesirable side effects such as bone loss, and abnormal lipid metabolism. Inhibition of
aromatase expression by inactivating breast tumor-specific aromatase promoters can selectively block estrogen
production at the tumor site. Although several synthetic chemical compounds and nuclear receptor ligands are known
to inhibit the activity of the tumor-specific aromatase promoters, further development of more specific and efficacious
drugs without adverse effects is still warranted. Plants are rich in chemopreventive agents that have a great potential to
be used in chemotherapy for hormone dependent breast cancer which could serve as a source for natural AIs. In this
brief review, we summarize the studies on phytochemicals such as biochanin A, genistein, quercetin, isoliquiritigenin,
resveratrol, and grape seed extracts related to their effect on the activation of breast cancer-associated aromatase
promoters and discuss their aromatase inhibitory potential to be used as safer chemotherapeutic agents for specific
hormone-dependent breast cancer.
Background
Aromatase is a member of the cytochrome P450 enzyme
f a m i l ya n dap r o d u c to ft h eCYP 19A1 gene [1]. This
membrane-bound protein (aromatase) is the rate limiting
enzyme in the conversion of androstenedione to estrone
(E1) and of testosterone to estradiol (E2) (Figure 1).
Aromatase consists of two components: the hemoprotein
aromatase cytochrome P450 encoded by the CYP19A1
gene and expressed only in steroidogenic cells, and the fla-
voprotein NADPH-cytochrome P450 reductase, expressed
ubiquitously in many cell types [2-4]. The enzyme (aroma-
tase) is localized in the endoplasmic reticulum of a cell,
and catalyzes three hydroxylation reactions that convert
androstenedione to E1 and testosterone to E2 [5,6]. The
enzyme activity is increased by alcohol, age, obesity, insu-
lin and gonadotropins [7]. The CYP19A1 gene is highly
expressed in the human placenta and in the granulosa
cells of the ovarian follicles. However, many nonglandular
tissues including liver, muscle, brain, bone, cartilage, blood
vessels, breast (both normal and carcinogenic) and adipose
tissues have lower level of CYP 19A1 expression under the
control of tissue-specific promoters [8]. Inhibition of aro-
matase enzyme activity has been shown to reduce estrogen
production throughout the body and aromatase inhibitors
(AIs) are being used clinically to retard the development
and progression of hormone-responsive breast cancer
[6,7].
The aromatase gene and tissue-specific promoter
expression
Human aromatase is a 58 kDa protein which was first
purified from placental microsomes in 1980s [9]. Only
recently has the crystal structure of human placental
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single copy of the CYP19A1 gene which is ~123 kb long,
located on the short arm of the chromosome 15 (15q21),
and is transcribed from the telomere to the centromere
[2,10-12]. The coding region spans 30 kb and includes
nine translated exons (II-X) with two alternative polyade-
nylation sites [2]. The ATG translation initiation site is
located on the exon II. There are a number of alternative
non-coding first exons (I.1, I.2, I.3, I.4, I.5, I.6, I.7, and
PII) which are expressed in tissue-specific manner, lie
upstream to the coding region and are spliced to a com-
mon acceptor sites in exon 2 [13-15] (Figure 2). The dis-
tal promoter I.1 which drives transcription in placenta is
located approximately 89 kb upstream of exon II. The
proximal promoter found immediately upstream of exon
II is PII which is expressed in the gonad. In between
these two promoters, several other first exons and pro-
moters have been identified, such as 2a in the placental
minor, I.3 in the adipose tissue specific promoter, I.4 in
the promoters in skin fibroblast and preadipocytes, I.5 in
fetal, I.6 in bone, I.f in brain, and I.7 in endothelial cells
[2,14,16-18]. As various tissues utilize their own promo-
ters and associated enhancers and suppressors, the tis-
sue-specific regulation of estrogen synthesis is very
complex. Due to the use of alternative promoters, aroma-
tase transcripts in various expression sites contain unique
5’-untranslated first exons, which are spliced onto the
coding exon II at the common 3’-splice site upstream of
the ATG translation start codon [14]. Although expres-
sion of the aromatase gene is under the control of dis-
tinct tissue-specific promoters, the coding region of
aromatase transcripts and the resulting protein is identi-
cal in all expression sites [9,14] and [19].
In healthy breast tissue, expression of CYP 19 is under
the control of promoter I.4 with synergistic actions of
class I cytokines such as IL-6, IL-11, tumor necrosis fac-
tor-a (TNF-a) and glucocorticoids [9,20-22]. In tumor-
ous tissue aromatase expression is switched to promoters
I.3 and II which are transactivated by protein kinase A
(PKA) and cAMP-dependent signaling pathways [8,23].
Depending on the microenvironment the promoter
switching in the malignant breast tissue results in the
enhancement of aromatase gene transcription, protein
expression, and the enzymatic activity compared to the
normal breast tissue. Moreover, this promoter switching
is the primary reason for the increased estrogen produc-
tion in adipose stromal cells surrounding the breast can-
cer [18,24,25]. Promoter I.7 is also considered to be a
novel breast cancer associated aromatase promoter situ-
ated midway between promoter I.4 and promoter I.3/II
[14,22]. Promoters I.3 and II lie 215 bp apart from each
other and are coordinately regulated by prostaglandin E2
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Figure 1 Schematic diagram of the reaction catalyzed by aromatase enzyme.
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Page 2 of 10(PGE2) via a cAMP-PKA-dependent pathway, and not by
cytokines as seen in normal breast tissue [8]. Signaling
effects/transcriptional regulators that mediate PGE2
action include the activator pathways p38/CREB-ATF
and JNK/jun and the inhibitory factor breast cancer 1
(BRCA1) in breast adipose fibroblasts [14,22].
Breast cancer and aromatase
Breast cancer is an important public health problem
worldwide. In the United States, breast cancer represents
the most common neoplasm and second most frequent
cause of cancer death in women [26]. Estrogens have
been implicated in the etiology of breast cancer and have
been added to the list of known human carcinogens
[27,28]. Estrogens are suggested to cause breast cancer by
stimulating cell growth and proliferation through recep-
tor-mediated processes and v i at h e i rg e n o t o x i cm e t a b o -
lites [29,30]; therefore, inhibition of estrogen production/
effect is nowadays a common practice for breast cancer
treatment [9]. The general strategies to inhibit estrogen
action are to block estrogen receptor (ER) binding to its
specific ligand or to disrupt estrogen production by alter-
ing the aromatase gene expression or enzyme activities
[15]. ER antagonists can block estrogenic actions; how-
ever, estrogen production can be inhibited by aromatase
inhibitors (AI).
It is very important to know that the E2 production site
in women changes with the increase of age [6]. In the
pre-menopausal period the ovaries are the major source
of aromatase and its substrate, androstenedione and thus
E2. In humans, androstenedione is produced by the theca
folliculi cells, and is converted to E1 and subsequently to
E2 in the granulosa cells by aromatase. Therefore, during
the reproductive years, E2 mainly works as an endocrine
factor acting on estrogen-sensitive tissues. In the post-
menopausal period the ovaries lose the expression of aro-
matase; however, they are still able to produce androste-
nedione. At this stage adrenal glands are the major
producer of androgens, which are converted to estrogens
in peripheral tissues such as liver, fat, muscle, skin, bone,
and mammary tissue [6,31-33]. In post-menopausal
women E2 synthesized in extragonadal sites acts locally
at these peripheral sites as intracrine, autocrine, paracrine
or juxtacrine factors, and acts directly in the cells that
synthesize estrogen or on the neighboring cells [34,35].
Moreover, in post-menopausal breast cancer patients, the
concentration of E2 in breast tissue is ~20-fold greater
than in plasma, suggesting that intratumoral estrogen
synthesis, its retention, and cellular uptake plays impor-
tant role in the progression of ER+ breast cancer [6,36].
Although the exact localization of aromatase in human
breast tumor is still controversial [37,38], in majority of
the breast cancer cases aromatase activity and aromatase
mRNA levels show higher levels than those observed in
non-malignant mammary tissues [39]; this supports the
concept that in-situ production of E2 by aromatase plays
a major role in breast cancer progression [40].
Considering the importance of E2 in hormone receptor
positive breast cancer, many therapeutic approaches have
been developed to deprive E2 signaling [7,9,15]. Two
main chemical approaches have been successfully utilized
[15]. The traditional method of E2 inhibition is to inter-
fere with E2 interaction with its receptors (ERa and ERb)
using selective estrogen receptor modulators (SERMs)
such as tamoxifen and raloxifene [41,42]. Another
approach is to reduce E2 signaling by using AIs to
decrease E2 synthesis [43]. While SERMs are effective
both in pre-and post-menopausal women, AIs are not
appropriate to use for pre-menopausal women, because
in pre-menopausal women, AIs, by lowering the E2
levels, stimulate the secretion of gonadotropins from the
pituitary gland. Subsequently, the gonadotropins stimu-
late the ovaries to produce estrogens which can counter-
act AIs effect and possibly causing ovarian cysts [44].
Moreover, due to indiscriminate reduction of aromatase
activity in all expression sites of the body, AIs can induce
many side effects such as bone loss, hepatic steatosis and
abnormal lipid metabolism [14,45-49]. Therefore it is
desirable to design selective aromatase modulators that
target the over-expression of this enzyme (aromatase) in
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Figure 2 Partial structure of human CYP19 gene. Human aromatase gene is located on chromosome 15 and transcribes from telomere
towards centromere. The aromatase gene is ~ 123 kb long contains nine coding exons (II-X) and two alternative polyadenylation sites. Partially
tissue specific promoters direct aromatase gene transcription.
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Page 3 of 10breast epithelial cells and surrounding fibroblasts, while
other sites of estrogen production remained unaltered
[50,51]. With this regard, selective inhibition of aroma-
tase promoter I.3/II activities may be a fruitful approach
to inhibit estrogen production in breast tumor while
allowing aromatase expression via alternative promoters
in other regions of the body like brain and bone.
Inhibitory agents of aromatase promoter I.3/II
There are several potential synthetic agents available for
inactivation of aromatase promoter I.3/II. Studies in
human breast adipose fibroblasts revealed that sodium
butyrate, peroxisome proliferator activated receptor g
(PPAR g) agonists, retinoid X-receptor (RXR) agonists,
and inhibitors of p38 and JNK are capable of inhibiting
aromatase promoter I.3/II activity. The action of these
agents has been summarized in a recent review by Chen
et al [14]. However, these synthetic products are also
known to induce side effects. Troglitazone, rosiglitazone
and pioglitazone are PPARg agonists (FDA approved rosi-
glitazone and pioglitazone for the treatment of type 2 dia-
betes). These drugs caused edema, reduced hemoglobin
and hematocrit levels, increased plasma LDL-and HDL
cholesterol and increased body weight [52-55]. The RXR
agonist LG101305 (the FDA approved drug is bexarotene)
induced hypertriglyceridemia, hypercholesterolemia,
hypothyroidism and leucopenia. Sodium butyrate induced
bradycardia [55-57] while p38 inhibitor SB202190 is toxic
to liver and the JNK inhibitor AS601245 have no reported
side effects compared to others [58-60].
Natural products targeting aromatase gene
promoters
With the clinical success of several synthetic AIs in the
treatment of postmenopausal ER-positive breast cancer,
researchers have also been focused onto the potential of
natural products as AIs [61]. These compounds (natural
products) are mostly obtained from terrestrial and marine
organisms and are still in the forefront of drug discovery.
Moreover, the rich structural diversity and complexity of
these compounds prompted the researchers to synthesize
them in the laboratory for therapeutic applications. Many
chemopreventive drugs used today are derived from the
natural products [62-68]. In addition, many natural pro-
ducts that have been used traditionally for nutritional or
medicinal purposes as botanical dietary supplements
(BDS) may also afford as AIs with reduced side effects
[61,69,70]. Because many natural products are associated
with low toxicity, they are potentially excellent candidates
for use as chemopreventive agents [71-73]. Epidemiologi-
cal evidence suggests that women living in Asia, where
diets have traditionally included soybean products, report
fewer postmenopausal symptoms and experience fewer
breast cancers than women in Western countries [74-77].
More specifically, Asian women have a 3-fold lower breast
cancer risk than women in the United States, independent
of body weight [78]. Furthermore, serum concentrations
of E2 are 40% lower in Asian women compared with their
Caucasian counterparts [79]. Thus, environmental and
dietary factors may explain at least some of the discre-
pancy in breast cancer risk between Asian and western
populations [74,75]. Despite the known AIs, there is still a
need of searching for new AIs from natural products for
future drug development [68]
Among the natural products tested as AIs, phytoestro-
gens, such as flavones and isoflavones are able to bind ER
and induce estrogen action [77]. The binding characteris-
tics and the structural requirements necessary for the inhi-
bition of human aromatase by flavones and isoflavones
were obtained by using computer modeling and confirmed
by site-directed mutagenesis [80-82]. It was found that
these compounds bind to the active site of aromatase in
an orientation in which their rings A and C mimic rings D
and C of the androgen substrate, respectively [80]. Until
now ~ 300 natural products, most of them are phytoestro-
gens, have been evaluated for their ability to inhibit aro-
matase using noncellular (mostly using human microsome
as a source of aromatase enzyme), cell-based, and in vivo
aromatase inhibition assays [61,83-85]; however, only a
few studies (biochanin A from red clover, genistein from
soybean, quercetin, isoliquiritigenin from licorice, resvera-
trol from grape peel and extracts of grape seeds, Figure 3)
have been reported for their effect on aromatase promoter
I.4, I.3/II activity [86-91]. The exact mechanisms how
these plant products adapted to inhibit aromatase gene
expression or enzyme activity is not fully understood.
Biochanin A (5, 7-dihydroxy-4’-methoxyisoflavone) is an
isoflavone extracted from red clover (Trifolium pretense)
by Pope et al. [92]. The first evidence that red clover has
estrogenic activity were reported by Bennets et al. [93]
after observing breeding problems of sheep grazing on red
clover pastures which have been attributed to the isofla-
vone and coumestrol content of red clover. Serious fertility
disturbances indicating estrogenic stimulation of cattle fed
with red clover silage were reported [94-96]. Although bio-
chanin A was moderately active in inhibiting microsomal
aromatase activity (IC50: 5-10 μM) but was strongly active
when tested in JEG-3 cells (human placental choriocarci-
noma cell line). However, it did not inhibit aromatase
activity in granulosa-luteal cells, and human preadipocyte
cells and was also inactive in trout ovarian aromatase
assay [61]. Interestingly, in MCF-7 cells (ER-positive breast
cancer cells) biochanin A exhibited a dual action. It inhib-
ited aromatase activity at low concentrations, but was
estrogenic at high concentrations [97]. Furthermore, in
SK-BR3 cells (ER-negative breast cancer cells) biochanin A
was reported to inhibit aromatase enzyme activity and
reduce mRNA expression. By using a luciferase reporter
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Page 4 of 10gene assay it was demonstrated that this phytochemical
(biochanin A) was able to suppress the activation of
breast-specific promoter I.3/II [88]. However, it is not
known whether this inhibition is mediated through a
PGE-2 or cAMP dependent PKA mechanisms. When gen-
istein (a major metabolite of biochanin A) was tested in
the same model, it was also found to suppress promoter
I.3/II activation and showed an inhibition of aromatase
enzyme activity [88]. Therefore, the inhibitory effect of
biochanin A on aromatase promoter activation was sug-
gested by the authors to be due to its metabolic conver-
sion to genistein rather than its direct effect [88].
Genistein is a major phytoestrogen isolated from soy-
bean, a potential nutraceutical, geared for women suffer-
ing from perimenopausal symptoms [98-101]. Genistein
is also found in a number of other plants such as fava
beans, lupin, kudzu, and psoralea [102]. Genistein is
believed to be a chemopreventive agent against various
types of cancers, including prostate, cervix, brain, breast,
esophagus and colon [103]. Genistein was shown to
increase aromatase activity in human adrenocortical car-
cinoma (H295R) cells and in isolated rat ovarian follicles
[104,105]. Dietary genistein, which produced circulating
concentrations consistent with human exposures, did not
act as an aromatase inhibitor; rather, dietary intake of
genistein negated the inhibitory effect of an aromatase
inhibitor letrozole (a 3
rd generation aromatase inhibitor),
by stimulating the growth of aromatase-expressing estro-
gen-dependent breast tumors [106]. This study raises
concerns about the consumption of genistein-containing
products by postmenopausal women with advanced
breast cancer who may be treated with letrozole. Genis-
tein suppressed promoter I.3/II transactivity in SK-BR-3
cells (an ER-negative breast cancer cell line), however, in
HepG2 cells, genistein was found to induce promoter-
specific aromatase mRNA expression with significant
increases in promoters I.3 and II [89]. In addition, the
phosphorylated forms of PKCa, p38, MEK and ERK1/2
kinases were also induced in HepG2 cells by genistein
[89]. There are also some reports of a weak inhibition of
biochaninA genistein
quercetin
epicatechin
(oneofthebuildingblocksofproanthocyanidins)
isoliquiritigenin resveratrol
Figure 3 The chemical structures of biochanin A, genistein, quercetin, epicatechin, isoliquiritigenin, and resveratrol.
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Page 5 of 10aromatase enzyme activity by genistein as well [80,107]
and a decrease in the transcription of Cyp19 mRNA in
human granulosa luteal cells [108].
Quercetin is one of the most abundant flavonols found
in plants. Quercetin was found to inhibit human aroma-
tase activity in placental microsomes [109]. When tested
in cellular systems utilizing adrenocortical carcinoma
cells, preadipocyte cells, or in co-culture experiments, it
exhibited either a mild or no effect [86,110,111]. In the
primary culture of human granulosa-luteal cells quercetin
was able to reduce aromatase mRNA expression in a
dose-dependent manner after an exposure period of 48 h
[108]. In another study, H295R human adrenocortical
carcinoma cells were exposed to quercetin for 24 h and
an increase in aromatase enzyme activity was observed at
lower concentration, while a decrease in the enzyme
activity was observed at higher concentrations [105].
Quercetin increased p II and I.3-specific aromatase tran-
scripts about 2.6-and 2-fold in H295R cells after 24 h
exposure probably by enhancing intracellular cAMP
levels [105].
Isoliquiritigenin, a flavonoid from licorice (Glycyrrhiza
glabra), was found to be an inhibitor of aromatase enzyme
activity in vitro [90]. Moreover, this compound was able to
block MCF-7aro cells(MCF-7 cells stably transfected with
CYP19) growth and when added in diet inhibited signifi-
cantly the xenograft growth in ovariectomized athymic
mice transplanted with MCF-7aro cells [90]. Isoliquiriti-
genin also inhibited aromatase mRNA expression and sup-
pressed the activity of CYP19 promoters I.3 and II [90] in
MCF-7 cells. Furthermore, binding of C/EBP to PII pro-
moter of CYP19 was suppressed by isoliquiritigenin [90].
This study indicated that isoliquirititigenin has the poten-
tial to be used as a tissue-specific aromatase inhibitor in
breast cancer.
The aromatase inhibitory activity of grapes and grape
seed extracts (GSE) has been studied by many investiga-
tors [61,83,91]. The active chemicals found in grapes and
red wine are procyanidin dimers that are also present in
high concentrations in grape seeds [87]. GSE is composed
of about 74-78% of proanthocyanidins and <6% of free fla-
vanol monomers such as catechin, epicatechin, and their
gallic acid esters [87]. Through the suppression of the
expression of CREB-1 and glucocorticoid receptor (GR),
grape seed extracts (GSE) has been found to decrease the
expression of aromatase in MCF-7 and SK-BR-3 cells by
suppressing the activity of promoters I.3/II, and I.4 in a
dose-dependent manner [87]. The GSE (IH636) is in
phase I clinical trials for the prevention of breast cancer in
postmenopausal women who have an increased risk of
breast cancer development [61].
The grape peel contains resveratrol, a polyphenolic com-
pound which has structural similarity with estrogen [91].
This nonflavonoid phytoestrogen inhibited aromatase
activity in MCF-7aro cells. In SK-BR-3 cells resveratrol
significantly reduced aromatase mRNA and protein
expression in a dose-dependent manner [91]. Moreover,
this compound was able to repress the transactivation of
CYP19 promoters I.3 and II in SK-BR-3 cells [91], which
indicate that resveratrol could be able to reduce localized
estrogen production in breast cancer cells.
Future directions
The expected direct outcome of aromatase inhibition is
the maintenance of low levels of estrogen in the breast
and surrounding adipose tissue. Understanding the mole-
cular mechanism by which aromatase promoters I.4 and
I.3/II are regulated is clinically significant and useful for
developing new drugs. Although only a few plant products
have been documented to mediate their effects through
aromatase promoters, there are many more potent natural
products (such as white button mushroom (Agaricus bis-
porus) which is in phase I trials [83]) which could be
potential candidates for future study. Moreover, accumu-
lating evidence suggests that beside transcription factors
and co-regulators there are many other factors such as
cyclooxygenases (COX) which are involved in tissue-speci-
fic aromatase promoter regulation [112,113]. Selective
COX inhibitors from natural products can be used to sup-
press CYP19A1 gene expression. Studies also indicate that
CYP 19A1 regulations are also under epigenetic control,
including DNA methylation, and histone modification,
which can add a new layer of complexity in the regulation
of the aromatase gene [114]. DNA methylation generally
occurs in gene promoters where the CpG rich dinucleo-
tides are located. However, DNA methylation of CpG-
poor promoter regions has also been shown as a mechan-
ism of mediating tissue-specific gene transcription through
the inhibition of transcription factor binding [115,116].
Aromatase promoter I.3/II has six CpG dinucleotides sub-
jected to methylation of cytosines and can be considered
as CpG-poor promoter. However, in human skin fibro-
blasts hypermethylation of almost all six CpG sites
resulted in markedly reduced aromatase promoter I.3/II
activity, whereas hypomethylation of only two of the six
sites led to increased promoter activity associated with an
increase in cAMP [14]. In contrast to these studies, in
breast adipose fibroblasts (BAF) promoter I.4 and I.3/II
derived mRNA were not dependent on the CpG methyla-
tion status within respective aromatase promoters [114].
Further, DNA methylation is catalyzed by DNA methyl
transferases (DNMTs). Inhibition of DNA methylation by
5-aza-2’-deoxycytidine, which is also a specific DNMT
inhibitor, increased CYP19 mRNA expression in BAFs and
breast cell lines [114]. These studies indicate that disrup-
tion in epigenetic regulation may give rise to increase in
aromatase levels in the breast [114]. There are many syn-
thetic chemicals that are undergoing clinical trials to be
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ment [117]. The major problems of these drugs are the
unwanted side effects. Many natural products have the
potential to be used as better epidrugs than synthetic epi-
drugs. One of the best examples is (-) - epigallocatechin-3-
gallate from green tea which is used as demethylating
agents for breast cancer patients [118-120]. Therefore
extensive investigations in natural products seem promis-
ing or necessary.
Conclusions
Aromatase is a well-established molecular target and the
AIs are proving to be an effective new class of agent for the
chemoprevention of breast cancer. Regulation of aromatase
expression in human tissues is a complex phenomenon,
involving alternative promoter sites that provide tissue spe-
cific control. The promoters I.3 and II are the major pro-
moters directing aromatase expression in breast cancer.
The drugs that can selectively inhibit aromatase expression
may be useful to obviate side effects induced by the nonse-
lective AIs. Although many synthetic chemicals are used to
inhibit tissue-specific inactivation of aromatase promoters
I.3 and II, in the literature only a few natural products (we
have included six of them) have been reported with such
activities. More studies on natural products are necessary
to find an appropriate tissue-specific AI.
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